Will 2026 deliver a fourth straight year of double-digit returns? Kevin Matras says yes! Make sure youre ready to fully benefit from this broadening bull run.
ANI Pharmaceuticals rare disease growth, led by surging Cortrophin Gel sales, is outpacing Tevas slower sales momentum in this head-to-head stock comparison.
Following a careful analysis of the Zacks Oil and Gas - Exploration and Production - Canadian industry, we advise focusing on shares of CNQ, IPOOF and GTE.
The Zacks Manufacturing - Electronics industry gains from strength across major end markets. ETN, EMR, ENS and POWL are some notable stocks in the industry.
Amid macroeconomic volatility, growing global connectivity bodes well for Zacks Satellite and Communication industry participants, such as GSAT, IRDM and GILT.
Goldman Sachs and Morgan Stanley delivered the most impressive bottom-line performance during Q4, while BlackRock continued to dominate in regard to investment assets.
The U.S. Commerce Departments 25% national security tariff on certain high-end semiconductors announced on Wednesday is a "phase one" action to protect the sector and could be followed by other announcements pending negotiations with other countries and companies, a White House official said on Thursday.
Gold slipped the most in more than two weeks after US President Donald Trump expressed reluctance about nominating Kevin Hassett as Federal Reserve chair, casting further doubt over his search for the next head of the central bank.
Taiwan Semiconductor Manufacturing Companys shares soared 5% intraday on Thursday, reaching a new 52-week high. This followed its fourth-quarter earnings report on January 15, which fueled optimism about artificial intelligence. As it beat Wall Street expectations, buoyed by AI investment from ...
TORONTO, Jan. 15, 2026 (GLOBE NEWSWIRE) -- Q-Gold Resources Ltd. (TSXV: QGR; OTCQB: QGLDF; Börse Frankfurt: QX9G) (“QGold” or the “Company”) is pleased to announce, that, subject to regulatory approval, it has engaged the services of ICP Securities Inc. (“ICP”) to provide automated market making services, including use of its proprietary algorithm, ICP Premium™, in compliance with the policies and guidelines of the TSX Venture Exchange and other applicable legislation. ICP will be paid a month...
URBANA, Ill.--(BUSINESS WIRE)--Frasca International, Inc., ein Unternehmen von FlightSafety International, gab heute bekannt, dass es einen Vertrag mit Global Medical Response (GMR) über die Lieferung von vier neuen Flugtrainingsgeräten (FTDs) der Stufe 7 unterzeichnet hat. Zu den neuen Geräten gehören ein Airbus EC135, eine Pilatus PC-12, eine Beechcraft C90 und eine Beechcraft B200. Jedes FTD-System wird mit dem einzigartigen Bewegungssystem von Frasca ausgestattet sein, um einen erhöhten Rea
BALTIMORE, Jan. 15, 2026 (GLOBE NEWSWIRE) -- Adams Natural Resources Fund, Inc. (NYSE: PEO) announces the Fund’s investment returns for 2025. The total return on the Fund’s net asset value for 2025 was 9.4%, with dividends and capital gains reinvested. The comparable figures for the S&P 500 Energy Sector and the S&P 500 Materials Sector were 8.7% and 10.5%, respectively. Our benchmark, which is comprised of the S&P 500 Energy Sector (80%) and the S&P 500 Materials Sector (20%), returned 9.1%. ...
SHELTON, Conn., Jan. 15, 2026 (GLOBE NEWSWIRE) -- Acme United Corporation (NYSE American: ACU) today announced that it has acquired the assets of SLED Distribution, LLC. (d/b/a “My Medic”), a leading supplier of tactical, trauma and emergency response products, primarily in the direct-to-consumer channel. . My Medic had revenues in 2025 of approximately $19 million. Established in 2014, the company is located in North Salt Lake, Utah and employs 40 people.
Der deutsche Stahlhersteller soll von einem US-Konkurrenten übernommen werden. Die Amerikaner sind dafür bereit, einen deutlichen Aufschlag auf den Aktienkurs zu zahlen.
BALTIMORE, Jan. 15, 2026 (GLOBE NEWSWIRE) -- Adams Diversified Equity Fund, Inc. (NYSE: ADX) announces the Fund’s investment returns for 2025. The total return on the Fund’s net asset value for 2025 was 18.9%, with dividends and capital gains reinvested. The comparable figures for the S&P 500 Index and Morningstar U.S. Large Blend Category were 17.9% and 16.2%, respectively. The total return on the Fund’s market price for the period was 25.7%.
ZÜRICH, PHILADELPHIA UND KOPENHAGEN, Dänemark--(BUSINESS WIRE)--InterAx Biotech Ltd („InterAx“) und Alveus Therapeutics Inc. („Alveus“) haben heute eine strategische Forschungskooperation und Lizenzvereinbarung zur Entwicklung eines differenzierten niedermolekularen Arzneimittelkandidaten für Stoffwechselerkrankungen bekannt gegeben, der eine dauerhafte Gewichtsreduktion bei hervorragender Verträglichkeit verspricht. Im Rahmen dieser Partnerschaft wird eine gemeinsame Forschungsinitiative zu ei